Richard S. Finn, MD, Geffen School of Medicine
Advertisement
Articles by Richard S. Finn, MD, Geffen School of Medicine
Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.
HCC: Applying Recent Data Into Practice
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Emerging Therapies Under Investigation
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Combination Regimens for HCC Treatment
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Emerging Biomarkers in Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Liver Function and Treatment Decisions
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Safety Profiles of Novel Therapies for HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Sequencing of Novel Therapies in HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Regorafenib or Cabozantinib for Second-Line HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Selecting Second-Line Therapy for HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Second-Line Treatment for Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Novel Combinations to Treat HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Immunotherapy in Liver Cancer
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Treating Patients With Atezolizumab/Bevacizumab
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
IO and VEGF Inhibition in Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Advertisement
Latest Updated Articles
Emerging Biomarkers in Hepatocellular CarcinomaJuly 13th 2020
Screening Vs Diagnosis: Assessing Liver FunctionOctober 30th 2020
Immunotherapy Monotherapy in Later-Line SettingOctober 30th 2020
Regorafenib or Cabozantinib for Second-Line HCCJuly 13th 2020
HCC: Emerging Therapies Under InvestigationJuly 13th 2020
Hepatocellular Carcinoma: Diagnostic Work-UpJuly 13th 2020
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5